Tatva Chintan Pharma IPO

Tatva Chintan Pharma Chem Limited is one of the largest manufacturers of SDAs for zeolites in the country. The company specialises in phase transfer catalysts, structure-directing agents and agrochemical intermediates, and several other speciality chemicals.
In FY2020, Tatva Chintan Pharma generated 76% of its revenue from exports. The company exports its products to more than 25 countries globally. It has a robust customer base in industries like automotive, petroleum, agrochemicals, pharmaceutical dyes and pigments, personal care, and paints and coatings.

IPO objectives

- Obtain funds for expanding Dahej manufacturing facility.
- To fund the upgradation of the company’s R&D facilities in Vadodara.
- For addressing general corporate purposes.

Tatva Chintan Pharma IPO - Details

The offer size of Tatva Chintan Pharma IPO is Rs. 500 crores. The company will issue new equity shares amounting to Rs. 225 crores and offer for sale by unitholders and promoters totalling Rs. 275 crores.

Opening Date

July 16, 2021

Closing Date

July 20, 2021

Price Band

₹1073 to ₹1083

per equity share

Issue Size

₹ 500 Cr

Face Value

₹10

per equity share

Market Lot

13 Shares

Opening Date

July 16, 2021

Closing Date

July 20, 2021

Price Band

₹1073 to ₹1083

per equity share

Issue Size

₹ 500 Cr

Face Value

₹10

per equity share

Market Lot

13 Shares

Listing at NSE, BSE

Tatva Chintan Pharma IPO Important Dates

IPO Open Date 16-Jul-21
IPO Close Date 20-Jul-21
Basis Of Allotment Date 22-Jul-21
Initiation Of Refunds 26-Jul-21
Credit Of Shares To
Demat ACcount
28-Jul-21
IPO Listing Date 29-Jul-21 (tentative)
Initiation of Refund 27-Jul-21

Tatva Chintan Pharma IPO Latest News and Subscription Status Today [Live]

At 05:00 p.m.

- This IPO has been subscribed 180.35x by 5:00 PM. on Day 3
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 185.23x
- (NII) Non-institutional buyers: 512.22x
- (RII) Retail Individual buyers: 35.34x

At 04:00 p.m.

- This IPO has been subscribed 179.62x by 4:00 PM. on Day 3
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 185.23x
- (NII) Non-institutional buyers: 509.93x
- (RII) Retail Individual buyers: 4.384x

At 02:45 p.m.

- This IPO has been subscribed 134.31x by 2:45 PM. on Day 3
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 107.58x
- (NII) Non-institutional buyers: 406.65x
- (RII) Retail Individual buyers: 32.86x

At 01:45 p.m.

- This IPO has been subscribed 53.19x by 1:45 PM. on Day 3
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 18.85x
- (NII) Non-institutional buyers: 187.44x
- (RII) Retail Individual buyers: 15.26x

At 12:45 p.m.

- This IPO has been subscribed 31.07x by 12:45 PM. on Day 3
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 2.60x
- (NII) Non-institutional buyers: 108.80x
- (RII) Retail Individual buyers: 14.03x

At 11:35 a.m.

- This IPO has been subscribed 9.37x by 11:35 AM. on Day 3
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 2.55x
- (NII) Non-institutional buyers: 9.63x
- (RII) Retail Individual buyers: 13.16x

At 10:30 a.m.

- This IPO has been subscribed 8.11x by 10:30 AM. on Day 3
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.71x
- (NII) Non-institutional buyers: 8.27x
- (RII) Retail Individual buyers: 12.28x

At 05:00 p.m.

- This IPO has been subscribed 6.86x by 5:05 PM. on Day 2
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.71x
- (NII) Non-institutional buyers: 4.94x
- (RII) Retail Individual buyers: 11.21x

At 04:35 p.m.

- This IPO has been subscribed 6.65x by 4:35 PM. on Day 2
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.71x
- (NII) Non-institutional buyers: 4.35x
- (RII) Retail Individual buyers: 11.03x

At 04:05 p.m.

- This IPO has been subscribed 6.32x by 4:05 PM. on Day 2
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.50x
- (NII) Non-institutional buyers: 4.13x
- (RII) Retail Individual buyers: 10.59x

At 02:35 p.m.

- This IPO has been subscribed 5.48x by 2:35 PM. on Day 2
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.50x
- (NII) Non-institutional buyers: 2.40x
- (RII) Retail Individual buyers: 9.65x

At 12:50 p.m.

- This IPO has been subscribed 4.83x by 12:50 PM. on Day 2
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.50x
- (NII) Non-institutional buyers: 1.84x
- (RII) Retail Individual buyers: 8.59x

At 11:50 a.m.

- This IPO has been subscribed 4.25x by 11:50 AM. on Day 2
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.50x
- (NII) Non-institutional buyers: 1.40x
- (RII) Retail Individual buyers: 7.62x

At 10:40 a.m.

- This IPO has been subscribed 3.13x by 10:40 AM. on Day 2
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.50x
- (NII) Non-institutional buyers: 0.63x
- (RII) Retail Individual buyers: 5.71x

At 05:00 p.m.

- This IPO has been subscribed 2.46x by 5.00 PM. on Day 1
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.50x
- (NII) Non-institutional buyers: 0.38x
- (RII) Retail Individual buyers: 4.47x

At 04:05 p.m.

- This IPO has been subscribed 3.73x by 4.05 PM. on Day 1
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.50x
- (NII) Non-institutional buyers: 0.73x
- (RII) Retail Individual buyers: 6.85x

At 03:05 p.m.

- This IPO has been subscribed 3.15x by 3.05 PM. on Day 1
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.01x
- (NII) Non-institutional buyers: 0.61x
- (RII) Retail Individual buyers: 6.04x

At 01:58 p.m.

- This IPO has been subscribed 2.68x by 1:58 PM. on Day 1
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.01x
- (NII) Non-institutional buyers: 0.43x
- (RII) Retail Individual buyers: 5.18x

At 12:53 p.m.

- This IPO has been subscribed 2.16x by 12:53 PM. on Day 1
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.01x
- (NII) Non-institutional buyers: 0.33x
- (RII) Retail Individual buyers: 4.18x

At 11:58 a.m.

- This IPO has been subscribed 1.48x by 11:58 AM. on Day 1
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: 0.00
- (NII) Non-institutional buyers: 0.12x
- (RII) Retail Individual buyers: 2.91x

At 11:00 a.m.

- This IPO has been subscribed 0.93x by 11:00 AM. on Day 1
- It is a public issue of 32,61,882 equity shares.

Status of Subscription

- (QIB) Qualified institutional buyers: xxx
- (NII) Non-institutional buyers: 0.04x
- (RII) Retail Individual buyers: 1.84x

Why should you invest in Tatva Chintan Pharma IPO?

Tatva Chintan Pharma Chem is a niche player in the space of speciality chemicals. Moreover, when compared to its market peers, the company’s IPO issue price is reasonable.

Financial highlights

In FY2022, so far, the company’s exports stand at Rs. 211.99 crores, accounting for 70.58% of its revenue from operations.

Financial year Total Revenue Total Assets Profit after tax
March 31 2019 Rs. 2,068.01 million Rs. 1,875.08 million Rs. 205.43 million
March 31 2020 Rs. 2,646.22 million Rs. 2,489.38 million Rs. 377.89 million
March 31 2021 Rs. 3,062.92 million 3,148.03 million Rs. 522.62 million

How to apply for Tatva Chintan Pharma IPO?

You can apply for the Tatva Chintan Pharma IPO in these ways:

UPI
Link your bank account to a reliable UPI ID and register it with your Angel Broking account. Proceed to book Tatva Chintan Pharma IPO shares using the ID, confirm the payment on the UPI app, and block the amount for allotment.

Demat Account

1. If you are already a client of Angel Broking, apply directly for Tatva Chintan Pharma IPO, click here.
2. If you’re a new investor Open DEMAT Account for free with Angel Broking to begin your investment journey.

Tatva Chintan Pharma IPO - Noteworthy Highlights

These are a few noteworthy highlights of Tatva Chintan Pharma –

- It is India’s leading manufacturer of phase transfer catalyst and structure-directing agents.
- The company has a strong foothold in over 25 countries.
- It boasts a strong customer base across several crucial industries.
- Its clientele includes SRF, Laurus Laboratories, Asian Paints, Merck and Divis Laboratories, and Bayer.
- Its key products, namely methyl triocyl ammonium chloride and methyl tributyl ammonium chloride are likely to register more than 3% CAGR worldwide.

Tatva Chintan Pharma IPO - SWOT Analysis

strengths

Strengths

  • Global presence: It operates in more than 25 major countries across the globe. The global footprint offers it a competitive edge and greater exposure.
  • Strong financial standing: The company has registered growth in both its top and bottom lines. As of 31 March 2021, it clocked a debt-equity ratio of 0.54.
  • Diversified portfolio: A diversified portfolio has helped the company gain a sizeable market share in domestic and international markets.
Weaknesses

Weaknesses

  • Overdependence on exports: Nearly 75% of its revenue from operations comes from exports. This dependence on exports can limit its prospects.
Opportunities

Opportunities

  • Scope for growth: This company hasn’t reached its growth saturation level yet. Additionally, its global presence and diversified portfolio indicate upsides for further growth down the road.
Threats

Threats

  • Global market volatility: It generates a sizeable portion of its revenue from exports. This could pose a threat if economies of its major international markets suffer a financial crisis.
Competitive Analysis

Competitive Analysis

  • Tatva Chintan Pharma operates in a very competitive environment. Therefore, it is likely to face stiff competition from existing market competitors based in the domestic and international markets.

    However, the company’s well-spread portfolio offers it a competitive advantage over most of its peers. Some of its competitors include the likes of PI Industries Ltd, Dishman group and Pacific Organics Pvt. Ltd, Aarti Industries Ltd, Delta Finochem, and Fine Organic Industries Ltd.
Strenghts Strengths
Weaknesses Weaknesses
Opportunities Opportunities
Threats Threats

Strengths

  • Brand recognition: The company has a global footprint in more than 24 countries with a partnered network of over 1.5 million restaurants.
  • Business model: Zomato follows a B2C business model that connects customers to a wide network of restaurants. The company has an asset-less business model, giving it high financial leverage.
  • Marketing: Zomato follows a robustly creative marketing strategy both online and offline. Accordingly, it has a decent customer engagement and has over 11.2 million active users each month.
  • User-friendly: The Zomato app and web portal come with an easy-to-navigate UI.

Weaknesses 

  • Competition: Newer food delivery platforms with unique offerings are mushrooming now more than ever. It not only limits Zomato’s market expansion scope but also imposes a threat to its existing customer base.
  • Business model: Though Zomato’s business model is currently working in its favour, there are high chances tech developments could impose a foundational threat. If Zomato stops innovating and improving its customer service, its very successful business model could restrain its potential.

Opportunities 

  • Market expansion: Zomato is active in 25 countries. Moreover, it has not reached the saturation point yet. Therefore, given its current market momentum and growth potential, it can be expected that the food delivery service will witness upward mobility and rapid market expansion in the next couple of years.
  • Online users: The percentage of smartphones users with interest access is increasing every day. This opens up a great growth opportunity for Zomato to expand its target base and market presence.
  • Technological development: As the tech space continues to bring in newer innovations, it could open newer paths for Zomato to explore.

Threats 

  • Competition: Newer food delivery platforms with unique offerings are mushrooming now more than ever. It not only limits Zomato’s market expansion scope but also imposes a threat to its existing customer base.
  • Business model: Though Zomato’s business model is currently working in its favour, there are high chances tech developments could impose a foundational threat. If Zomato stops innovating and improving its customer service, its very successful business model could restrain its potential.

Tatva Chintan Pharma IPO FAQs

Who is the registrar for Tatva Chintan Pharma IPO?

Link Intime India Private Ltd is the registrar for Tatva Chintan Pharma IPO.

What is the minimum order quantity for Tatva Chintan Pharma IPO?

The minimum order quantity for this IPO is 13 shares.

Who are the lead managers of the Tatva Chintan IPO?

JM Financial and ICICI Securities are the book-running lead managers for Tatva Chintan Pharma IPO.

How many manufacturing units of Tatva Chintan Pharma are there?

Currently, there are two manufacturing units of Tatva Chintan Pharma in Dahej and Ankleshwar.

Enjoy Free Equity

Delivery Trade for Lifetime

Get the link to download the app

Enjoy Lifetime Free Delivery Trade

Download the app now

Or Scan below QR Code

to download App

Open an account